• Corpus ID: 79540728

Intérêt de l’augmentation du taux sanguin d’hydroxychloroquine dans le lupus cutané réfractaire à ce traitement : un essai prospectif en ouvert sur 34 patients

  title={Int{\'e}r{\^e}t de l’augmentation du taux sanguin d’hydroxychloroquine dans le lupus cutan{\'e} r{\'e}fractaire {\`a} ce traitement : un essai prospectif en ouvert sur 34 patients},
  author={François Chasset},
Introduction : Nous avons montre en introduction de ce travail, que pres d’un tiers des patients suivis pour un lupus cutane erythemateux (LEC) sont resistant a l’hydroxychloroquine (HCQ). Il semble exister des disparites en termes de reponse en fonction des differents sous-types de LEC meme si des etudes a plus grandes echelles sont necessaires pour valider cette observation. Objectif : evaluer l’efficacite de l’augmentation de la dose quotidienne d’HCQ sur la reponse cutanee dans le LEC… 


Chloroquine-quinacrine association in resistant cutaneous lupus.
Chloroquine quinacrine combination was useful not only in these conditions but also in patients with refractory cutaneous lesions of quiescent systemic lupus erythematosus (SLE) from March 1993 to June 1994.
Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Monitoring hydroxychloroquine blood concentrations might improve the management of refractory CLE and the statistical significance of correlation between blood hydroxy chloroquine concentration and efficacy of hydroxy chlorineoquine and the statistics in univariate and multivariate analyses of complete remission with several variables are studied.
Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study.
It is suggested that baseline lupus severity and SLE are predictors of response to hydroxychloroquine, and the effects of disease attributes and metabolizing cytochrome P450 (CYP) polymorphisms on clinical outcome are investigated.
Blood Concentrations of Hydroxychloroquine and Its Desethyl Derivative Correlate Negatively with the Percentage of CD45RO+ Cells among CD4+ Lymphocytes in Hydroxychloroquine‐Treated Lupus Patients
In lupus patients, HCQ and DHCQ may alter the generation or the blood circulation of CD4+CD45RO+ lymphocytes in a concentration‐dependent pattern.
Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus.
  • S. Kwatra
  • Medicine
    Journal of the American Academy of Dermatology
  • 2015
The meta-analysis by Chasset et al indicates that antimalarial drugs, including chloroquine and hydroxychloroquine (HCQ), are less effective in smokers compared to nonsmokers with cutaneous lupus erythematosus (CLE), and practitioners should strongly suggest smoking cessation to patients with CLE.
Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Hydxychloroquine-induced pigmentation was independently associated with previous treatment with oral anticoagulants and/or antiplatelet agents and with higher blood HCQ concentration, and the hypothesis that HCQ- induced pigmentation is secondary to ecchymosis or bruising is supported.
Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)
CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
Hydxychloroquine, which overall is well tolerated by patients with SLE, has a protective effect on survival which is evident even after taking into consideration the factors associated with treatment decisions.
Lupus erythematosus tumidus: a clinical and histological study of 25 cases
LET is a variant of CLE that has distinctive clinical, histologic and prognostic features and is not constant in patients diagnosed at Hospital Universitari Germans Trias i Pujol, Spain.
Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
It is indicated that patients with cutaneous LE who smoke are significantly less likely to respond to antimalarial therapy.